Last reviewed · How we verify
MK0803, lovastatin
Lovastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.
Lovastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia, Primary prevention of coronary heart disease.
At a glance
| Generic name | MK0803, lovastatin |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Lovastatin competitively binds to HMG-CoA reductase and blocks the conversion of HMG-CoA to mevalonate, a critical early step in the cholesterol biosynthetic pathway. This leads to decreased intracellular cholesterol production, upregulation of LDL receptors on hepatocytes, and enhanced clearance of LDL cholesterol from the bloodstream. The net result is a significant reduction in serum LDL cholesterol and triglycerides.
Approved indications
- Hypercholesterolemia
- Primary prevention of coronary heart disease
Common side effects
- Myalgia
- Elevated liver transaminases
- Headache
- Rhabdomyolysis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK0803, lovastatin CI brief — competitive landscape report
- MK0803, lovastatin updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI